Medical cost control and drug research and development under centralized drug procurement

1.
The overall volume of the pharmaceutical industry has declined, and competition among pharmaceutical companies has intensified

The centralized procurement of medicines ranges from 4+7, to expansion, to full coverage of all types of medicines.
There is no doubt that for the centralized procurement of medicines that have passed the consistency evaluation, the bid-winning company will get the dominant market share of this variety
.

Centralized procurement preferentially purchases varieties with large clinical consumption and high purchase amount, and the superior will survive the inferior
.
With the gradual increase in the decline, the unselected products will gradually fade out of the market, the trend of homogeneous competition will fade, the overall volume of the industry will decline, the profit margin of pharmaceutical companies will also decrease, and the competition between pharmaceutical companies will intensify
.

2.
Survival of the fittest is the norm, and bold innovation is the future

From the purpose of policy formulation, price reduction is only a means, and research and development is the focus
.
Compared with price cuts, the deeper significance of centralized drug procurement lies in the establishment of a mechanism for survival of the fittest, which forces pharmaceutical companies to innovate boldly
.

Judging from the results of the centralized procurement of four batches of drugs, the top domestic pharmaceutical companies have a greater advantage, and most of the winning varieties are concentrated in leading companies such as Qilu and Yangzijiang
.
As Chinese patent medicines and biological medicines are included in centralized procurement, and the number of injections increases, competition will undoubtedly intensify
.

In other words, only if pharmaceutical companies strive to lead the market in terms of quality and variety, can they gain greater market share
.

3.
The ultimate goal: to make the masses feel sick and use good medicine

Lower prices, higher quality, and better drugs are the most important significance of implementing centralized drug procurement
.

In the long run, policies such as the consistency evaluation of generic drugs and medical insurance control fees are a series of combination punches.
Centralized drug procurement is only one of them.
The ultimate goal is to make more people affordable and use good drugs
.
Especially in the current development of the epidemic, the rise of domestically produced innovative drugs is more conducive to China's getting rid of dependence on imported original research drugs
.

Therefore, for pharmaceutical companies, regardless of whether they participate in centralized drug procurement, they must adjust their future development strategies and recognize the future development direction of the industry.
This is the key to the survival of pharmaceutical companies
.

Enlightenment from the normalization of centralized drug procurement: R&D must be done under the cost control policy

How effective is the implementation of the centralized drug procurement policy? According to official statistics, the first three batches of nationally organized drug procurement involve a total of 112 varieties, and the average drop of selected products has reached 54%.
In 2020, the actual procurement volume has reached 2.
4 times the agreed procurement volume, and the overall cost savings exceeds 1,000.
100 million yuan
.

Looking at the overall situation, whether it is the consistency evaluation of generic drugs or the control of medical insurance fees, "price reduction" has always been the main theme of the pharmaceutical reform
.
Faced with the institutionalization and normalization of centralized procurement, some companies have significantly increased their R&D investment, further promoting the development of the pharmaceutical industry to higher quality
.

How to view the policy trend of medical expenses control in the era of centralized procurement? How should the R&D strategy of generic drugs and innovative drugs be laid out in the era of centralized procurement? In response to these problems faced by pharmaceutical companies in strategy formulation and drug R&D, "The Path to Medical Cost Control in the Era of Centralized Procurement and the Breakthrough Training Conference on Drug R&D Strategy" organized by Zhiyao Business School will take you "breakthrough"
.

As a major training meeting to start in 2021, CPhI Pharmaceutical Online solemnly invited Dr.
Zhang Ziran, a senior medical policy research expert, and Chen Hong, a special medical expert from the Foreign Experts Bureau, to sit on the scene to discuss the countermeasures of pharmaceutical companies with the participants
.
In the new year, regardless of senior management positions, R&D and marketing personnel in pharmaceutical companies, don't miss this opportunity to understand the trend of pharmaceutical regulatory supervision and learn the strategic layout of R&D!

Attach meeting information:

The road to medical cost control and drug research and development strategy breakthrough training meeting in the era of centralized procurement (click for details)

Time: May 14-15, 2021

trainer:

Zhang Ziran, senior medical policy research expert

Specially-appointed medical expert of Chen Hong Foreign Experts Bureau

Early bird price: 2300 yuan/person (as of April 26)

Group purchase price: 3 people, 20% discount

VIP Annual Card: Enjoy a 30% discount